BCM
MRTX

Bluefin Capital Management’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Bluefin Capital Management’s Portfolio MRTX Stock Details MRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-24,816
Closed -$2.83M – 578
2020
Q2 		$2.83M Buy
24,816
+15,044
+154% +$1.46M 0.24% 58
2020
Q1 		$751K Sell
9,772
-94,789
-91% -$8.5M 0.1% 149
2019
Q4 		$13.5M Buy
+104,561
New +$10.1M 0.9% 23

Other funds holding MRTX

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AH
Aviva Holdings New Providence, Bahamas $20.5M AUM 117.01% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Bluefin Capital Management's MRTX Position: Q3 2020 in Review

Bluefin Capital Management sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q3 2020, closing a stake of 24,816 shares — an estimated $2.83M sold.

Bluefin Capital Management first reported a position in MRTX in Q4 2019 and held it in 3 quarters. The position peaked at $13.5M in Q4 2019. 225 funds tracked by Wall St. Rank hold MRTX as of Q3 2020.

  • Bluefin Capital Management reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q3 2020 after selling out during the quarter.
  • Bluefin Capital Management sold 24,816 Mirati Therapeutics, Inc. Common Stock shares in Q3 2020, an estimated $2.83M.
  • Bluefin Capital Management first reported a position in Mirati Therapeutics, Inc. Common Stock in Q4 2019 and held it in 3 quarters.
  • Bluefin Capital Management's Mirati Therapeutics, Inc. Common Stock position peaked at $13.5M in Q4 2019.
  • 225 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q3 2020.

Based on Bluefin Capital Management's 13F filing for Q3 2020, filed 16 Nov 2020.